The most important AI company you've never heard of

Because this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products.

Get the full story on this secret AI company poised for massive growth

Violetta Cotreau net worth and biography

Violetta Cotreau Biography and Net Worth

CAO of Akebia Therapeutics

Presently, Violetta Cotreau occupies the position of Chief Accounting Officer & Senior Vice President at Akebia Therapeutics, Inc.

In the past she held the position of Senior Vice President & Controller at AMAG Pharmaceuticals, Inc.

She received an undergraduate degree from the University of Massachusetts Lowell.

How do I contact Violetta Cotreau?: The corporate mailing address for Ms. Cotreau and other Akebia Therapeutics executives is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. Akebia Therapeutics can also be reached via phone at (617) 871-2098 and via email at [email protected]. Learn More on Violetta Cotreau's contact information.
Has Violetta Cotreau been buying or selling shares of Akebia Therapeutics?: Violetta Cotreau has not been actively trading shares of Akebia Therapeutics during the last ninety days. Most recently, Violetta Cotreau sold 3,946 shares of the business's stock in a transaction on Monday, February 28th. The shares were sold at an average price of $2.15, for a transaction totalling $8,483.90. Learn More on Violetta Cotreau's trading history.
Who are Akebia Therapeutics' active insiders?: Akebia Therapeutics' insider roster includes Steven Burke (SVP), John Butler (CEO), Violetta Cotreau (CAO), Michel Dahan (COO), Steven Gilman (Director), and David Spellman (CFO). Learn More on Akebia Therapeutics' active insiders.
Are insiders buying or selling shares of Akebia Therapeutics?: During the last twelve months, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 346,557 shares worth more than $494,167.74. The most recent insider tranaction occured on February, 29th when COO Michel Dahan sold 8,661 shares worth more than $13,684.38. Insiders at Akebia Therapeutics own 3.8% of the company. Learn More about insider trades at Akebia Therapeutics.
Information on this page was last updated on 2/29/2024.

Violetta Cotreau Insider Trading History at Akebia Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/28/2022	Sell	3,946	$2.15	$8,483.90

Violetta Cotreau Buying and Selling Activity at Akebia Therapeutics

Akebia Therapeutics Company Overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $1.15

$1.12

$1.18

50 Day Range

MA: $1.51

$1.14

$2.24

2 Week Range

Now: $1.15

$0.78

$2.48

Volume

2,392,700 shs

Average Volume

4,092,990 shs

Market Capitalization

$241.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Urgent Nvidia Warning

From Altimetry | Ad

Could Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.

Click here to access…